FDA's Seyfert-Margolis On Companion Diagnostics Guidance
Executive Summary
Industry is anxiously awaiting guidance from FDA on the development of companion diagnostics for drugs that will inform efforts to move towards personalized medicine.
You may also be interested in...
FDA Companion Dx Draft Guidance: Broad In Scope, Limited In Detail
FDA's draft guidance on the development of companion diagnostics for drug therapies, released July 12, delivers on a promise to publicly outline how it will address review of those products, but at only 12 pages, it has left some in industry longing for more insight.
FDA Companion Dx Draft Guidance: Broad In Scope, Limited In Detail
FDA's draft guidance on the development of companion diagnostics for drug therapies, released July 12, delivers on a promise to publicly outline how it will address review of those products, but at only 12 pages, it has left some in industry longing for more insight.
FDA Releases Companion Dx Guidance Broad In Scope, Limited In Detail
FDA released long-awaited draft guidance on the development of drugs with companion diagnostics July 12, but the 12-page document’s concise nature left some in the industry longing for more insight.